NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free OPRX Stock Alerts $10.70 +0.28 (+2.69%) (As of 05:13 PM ET) Add Compare Share Share Today's Range$10.28▼$10.7650-Day Range$8.80▼$16.1752-Week Range$6.92▼$16.65Volume88,211 shsAverage Volume128,578 shsMarket Capitalization$194.53 millionP/E RatioN/ADividend YieldN/APrice Target$15.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get OptimizeRx alerts: Email Address OptimizeRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside48.2% Upside$15.86 Price TargetShort InterestHealthy3.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.49) to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.50 out of 5 starsComputer And Technology Sector357th out of 596 stocksBusiness Services, Not Elsewhere Classified Industry61st out of 92 stocks 3.4 Analyst's Opinion Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOptimizeRx has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.92% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in OptimizeRx has recently decreased by 4.48%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPRX. Previous Next 3.0 News and Social Media Coverage News SentimentOptimizeRx has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.36 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 5 news articles for OptimizeRx this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for OPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.49) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -10.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -10.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. About OptimizeRx Stock (NASDAQ:OPRX)OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.Read More OPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPRX Stock News HeadlinesApril 29, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for AbbVie: Future Growth Beyond Humira’s CompetitionApril 26, 2024 | globenewswire.comOptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ETMay 2, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 22, 2024 | americanbankingnews.comFinancial Comparison: OptimizeRx (NASDAQ:OPRX) & ICTS International (OTCMKTS:ICTSF)April 18, 2024 | globenewswire.comOptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) ReportApril 16, 2024 | globenewswire.comOptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsApril 13, 2024 | stockhouse.comOptimizeRx Named America's Fastest-Growing Company for Fifth Year in a RowApril 11, 2024 | finance.yahoo.comOptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a RowMay 2, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 11, 2024 | finance.yahoo.comOptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a RowApril 11, 2024 | globenewswire.comOptimizeRx Named America's Fastest-Growing Company for Fifth Year in a RowApril 6, 2024 | investorplace.com7 Top Undervalued Stocks Primed for a Multibagger RecoveryApril 4, 2024 | markets.businessinsider.comOptimizeRx: A Strong Buy on Strategic Acquisitions and Innovative Platform ExpansionApril 2, 2024 | au.lifestyle.yahoo.comTesla blames sales drop on Houthi attacks and arson in GermanyApril 1, 2024 | msn.comAriana Madix To Host ‘Love Island USA’ as Sarah Hyland Departs FranchiseApril 1, 2024 | au.news.yahoo.comCanoo spent double its annual revenue on the CEO’s private jet in 2023April 1, 2024 | finance.yahoo.comOptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 OPTIMIZERx Corp Earnings CallMarch 28, 2024 | investorplace.comOPRX Stock Earnings: OptimizeRx Beats Revenue for Q4 2023March 28, 2024 | msn.comOptimizeRx Q4 revenue $28.4MMarch 27, 2024 | msn.comOptimizeRx Q4 2023 Earnings PreviewMarch 27, 2024 | benzinga.com7OPRX : OptimizeRx Earnings PreviewMarch 25, 2024 | globenewswire.comOptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ETMarch 23, 2024 | seekingalpha.comOptimizeRx: Exponential Growth Drives The Valuation CheaperMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), AnaptysBio (ANAB) and REPRO-MED Systems (KRMD)March 11, 2024 | markets.businessinsider.comOptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023March 11, 2024 | globenewswire.comOptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023See More Headlines Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today5/02/2024Next Earnings (Confirmed)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees109Year FoundedN/APrice Target and Rating Average Stock Price Target$15.86 High Stock Price Target$20.00 Low Stock Price Target$13.00 Potential Upside/Downside+52.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,570,000.00 Net Margins-24.56% Pretax Margin-35.18% Return on Equity-7.72% Return on Assets-6.65% Debt Debt-to-Equity Ratio0.27 Current Ratio3.04 Quick Ratio3.04 Sales & Book Value Annual Sales$71.52 million Price / Sales2.65 Cash FlowN/A Price / Cash FlowN/A Book Value$6.97 per share Price / Book1.49Miscellaneous Outstanding Shares18,180,000Free Float17,384,000Market Cap$189.25 million OptionableOptionable Beta1.05 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. William J. Febbo (Age 55)CEO & Director Comp: $694.4kMr. Stephen L. Silvestro (Age 46)President Comp: $458.6kMr. Edward Stelmakh C.M.A. (Age 58)M.B.A., CFO & COO Comp: $547.05kMr. Andrew Jacob D'SilvaSenior Vice President of Corporate FinanceMr. Todd Inman (Age 68)Chief Technology Officer Ms. Marion K Odence-Ford (Age 59)General Counsel & Chief Compliance Officer Comp: $428.12kMaira AlejandraMedia Relations ManagerMs. Sheryl KearneyHuman Resources ManagerMr. Terence J. Hamilton (Age 59)Senior Vice President of Pharma Comp: $441.63kDr. Doug Besch (Age 42)Chief Product Officer More ExecutivesKey CompetitorsZeroFoxNASDAQ:ZFOXRimini StreetNASDAQ:RMNIDHI GroupNYSE:DHXSteel ConnectNASDAQ:STCNMarchexNASDAQ:MCHXView All CompetitorsInsiders & InstitutionsMirae Asset Global Investments Co. Ltd.Bought 44,576 shares on 5/1/2024Ownership: 0.245%BNP Paribas Financial MarketsBought 20,634 shares on 5/1/2024Ownership: 0.154%Rice Hall James & Associates LLCBought 59,141 shares on 4/23/2024Ownership: 2.211%Greenwood Capital Associates LLCBought 20,245 shares on 3/5/2024Ownership: 0.301%Quarry LPSold 4,188 shares on 2/20/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions OPRX Stock Analysis - Frequently Asked Questions Should I buy or sell OptimizeRx stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks. What is OptimizeRx's stock price target for 2024? 7 analysts have issued 12 month price objectives for OptimizeRx's stock. Their OPRX share price targets range from $13.00 to $20.00. On average, they predict the company's share price to reach $15.86 in the next twelve months. This suggests a possible upside of 48.2% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts. How have OPRX shares performed in 2024? OptimizeRx's stock was trading at $14.31 at the start of the year. Since then, OPRX shares have decreased by 25.2% and is now trading at $10.70. View the best growth stocks for 2024 here. When is OptimizeRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our OPRX earnings forecast. How can I listen to OptimizeRx's earnings call? OptimizeRx will be holding an earnings conference call on Tuesday, May 14th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) posted its quarterly earnings data on Tuesday, April, 16th. The company reported $0.11 earnings per share (EPS) for the quarter. The firm earned $28.37 million during the quarter. OptimizeRx had a negative net margin of 24.56% and a negative trailing twelve-month return on equity of 7.72%. What ETF holds OptimizeRx's stock? Jacob Forward ETF holds 11,982 shares of OPRX stock, representing 3.85% of its portfolio. What guidance has OptimizeRx issued on next quarter's earnings? OptimizeRx issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $100.0 million-, compared to the consensus revenue estimate of $104.7 million. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN). Who are OptimizeRx's major shareholders? OptimizeRx's stock is owned by a number of institutional and retail investors. Top institutional investors include Rice Hall James & Associates LLC (2.21%), Mirae Asset Global Investments Co. Ltd. (0.25%) and BNP Paribas Financial Markets (0.15%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OPRX) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressYour bank is lying to you.MyBankTrackerForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.